Participant flow

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. · Source last updated 2015-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal Chemotherapy: As prescribed

   id

   FG000

   title

   Chemotherapy

2. description

   Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal Chemotherapy: As prescribed Bevacizumab: Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.

   id

   FG001

   title

   Chemotherapy + Bevacizumab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         394

      2. group Id

         FG001

         num Subjects

         385

      type

      Died

   2. reasons

      1. group Id

         FG000

         num Subjects

         8

      2. group Id

         FG001

         num Subjects

         10

      type

      Lost to Follow-up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         411

      2. group Id

         FG001

         num Subjects

         409

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         410

      2. group Id

         FG001

         num Subjects

         409

      type

      Intention to Treat

   3. achievements

      1. group Id

         FG000

         num Subjects

         407

      2. group Id

         FG001

         num Subjects

         403

      type

      Received at Least One Dose

   4. achievements

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         14

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         402

      2. group Id

         FG001

         num Subjects

         395

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

This study enrolled 820 patients at 220 sites located in 15 countries in Europe and Saudi Arabia. Study AIO KRK 0504 enrolled 261 patients, and 559 patients subsequently enrolled in Study ML18147 when the study was transferred to Hoffmann LaRoche (in 2008).

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice